Evidence map›Paper›PMID 35150596›Full record

ArticlePediatric diabetes2022

COVID-19 vaccination in adolescents and young adults with type 1 diabetes: Glycemic control and side effects.

Barbara Piccini, Benedetta Pessina, Francesco Pezzoli, Emilio Casalini, Sonia Toni

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. COVID-19 vaccines and blood glucose control: Friend or foe?Human vaccines & immunotherapeutics · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. COVID-19 vaccination and diabetic ketoacidosis.World journal of diabetes · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Barbara PicciniDiabetology Unit, Meyer University Children's Hospital, Florence, Italy.ORCID 0000-0002-2684-8638
Benedetta PessinaDepartment of Pediatrics, Meyer University Children's Hospital, University of Florence, Florence, Italy.
Francesco PezzoliDepartment of Pediatrics, Meyer University Children's Hospital, University of Florence, Florence, Italy.
Emilio CasaliniDepartment of Pediatrics, Istituto Giannina Gaslini, University of Genova, Genoa, Italy.
Sonia ToniDiabetology Unit, Meyer University Children's Hospital, Florence, Italy.
Meyer Children's Hospital · ITIstituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTwo vaccines against SARS-CoV-2 are approved by the World Health Organization (WHO) for minors aged 12 years and over. Currently, people with both type 1 diabetes (T1D) and type 2 diabetes (T2D) are prioritized for vaccination.

objectiveTo evaluate possible glycemic control modification, insulin dose adjustment and adverse effects after COVID-19 vaccination in young T1D individuals, users of different technology levels.

methodsThirty-nine T1D individuals, who received a whole vaccination cycle of either Moderna or Pfizer- BioNTech vaccines, were enrolled, 24 of whom using advanced hybrid closed loop systems (AHCLs) and 15 using intermittently scanned continuous glucose monitoring (isCGM). Symptoms after each dose and the following variables were considered: time in range 70-180 mg/dl (TIR), time in different glucose ranges, mean glucose levels, coefficient of variation (CV), total daily dose (TDD) and bolus proportion

resultsNo significant differences in TIR, time in different glucose ranges, mean glucose levels, TDD, bolus proportion, were observed before and after any dose nor before and after the whole vaccination cycle. CV was significantly lower after the whole vaccination cycle (CV pre-vaccination 35.1 ± 6.9% vs. CV post-vaccination 33.5 ± 6.3%; p 0.031) in subjects treated by AHCLs. Side effects after the vaccination were mild and more frequent after the second dose. No severe adverse reactions were reported.

conclusionsCOVID-19 vaccination was safe and not associated with significant perturbation of glycemic control in adolescents and young adults with T1D. This information could be of clinical use when counseling families about SARS-CoV-2 vaccination in young people with T1D.

Indexed as

COVID-19COVID-19 VaccinesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2AdolescentBlood GlucoseBlood Glucose Self-MonitoringGlycemic ControlHumansHypoglycemic AgentsSARS-CoV-2VaccinationYoung AdultBlood GlucoseCOVID-19 VaccinesHypoglycemic Agentsadvanced hybrid closed loopchildrenCOVID 19 vaccinationmetabolic controltype 1 diabetes

Identifiers

PMID35150596
PMCPMC9115347
OpenAlexW4211077156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.